tbuckley/cabot-search huggingface dataset:
THU0083 Vitamin D, Disease Activity and CO Morbidities in Early Spondyloarthritis: Data from the “Desir” Cohort
Authors: I. Hmamouchi, S. Paternotte, D. Borderie, B. Combe, M. Dougados
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> A small subset of patients with presumed idiopathic intracranial hypertension are found to have isolated internal jugular vein stenosis (IJVS). <h3>Objective</h3> To review the current interventions used in patients who present with intracranial hypertension secondary to IJVS. <h3>Methods</h3> In December 2020, we performed a literature search on Pubmed/Medline and Scopus databases for original articles studying surgical and endovascular interventions used for intracranial hypertension in the setting of internal jugular vein stenosis. No date, patient population, or study type was excluded. <h3>Results</h3> All studies that included at least one case in which a surgical or endovascular intervention was used to treat IJVS were included. Selection criteria for patients varied, most commonly defined by identification of compression of the internal jugular vein. The 17 studies included in this review ranged from case reports to large single-center cohort studies. The most used surgical intervention was styloidectomy. Styloidectomy had an overall better outcome success rate (79%) than angioplasty/stenting (66%). No complications were recorded in any of the surgical cases analyzed. Outcome measures varied, but all studies recorded clinical symptoms of the patients. <h3>Conclusion</h3> Few current large cohort studies analyze surgical and endovascular interventions for patients with IJVS. Notably, the most common intervention is styloidectomy, followed by internal jugular vein stenting. By understanding the trends and experience of interventionalists and surgeons, more focused and larger studies can be performed to determine effective strategies with the best clinical outcomes.
Obstetrical Nursing for Nurses and Students.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COMPARISON OF RIGHT VENTRICULAR GLOBAL LONGITUDINAL STRAIN BETWEEN VENDER-DEPENDENT AND VENDER-INDEPENDENT TWO-DIMENSIONAL SPECKLE TRACKING SOFTWARE
Authors: Hiromitsu Seno, Kenya Kusunose, Hirotsugu Yamada, Yoshihito Saijo, Susumu Nishio, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Sata Masataka
Journal: Journal of the American College of Cardiology (2016)
Conduction of Visceral Pain
Authors: James C. White
Journal: New England Journal of Medicine (1952)

ALTHOUGH our Puritan ancestors may have thought that pain was a scourge of God to try the soul of man, few modern philosophers would agree with this concept. The attempt to control chronic pain by surgery constitutes a relatively new field of medical endeavor, and most of our knowledge about it dates from the advent of local anesthesia. The only suitable experimental animal is man himself, as even our closest furry relatives cannot tell us what they feel. Furthermore, as we shall see, cats, dogs and even monkeys are poor experimental animals, since there are known differences between their pathways . . .
Abstract 759: Discovery of MK-8033, a highly specific c-Met/Ron dual inhibitor for the treatment of cancer
Authors: Alan Northrup
Journal: Cancer Research (2010)

Abstract MK-8033 is a highly specific c-Met/Ron dual inhibitor currently under investigation in Phase I clinical trials for the treatment of cancer. The discovery of MK-8033 is described including the first public disclosure of its structure. Additionally, an X-ray co-crystal structure of MK-8033 with the activated form of c-Met will be discussed to address why, contrary to established dogma, an inhibitor of an activated kinase conformation can lead to high specificity. The in vitro and in vivo properties of MK-8033 as well as aspects of the structure-activity relationships in this class will also be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 759.
Abstract 4711: Targeted inhibition of STAT3 dimerization by garcinol suppresses the growth of human hepatocellular carcinoma <i>in vitro</i> and <i>in vivo</i>.
Authors: Muthu K. Shanmugam, Snehajyoti Chatterjee, Rajendran Peramaiyan, Feng Li, Parijat Senapati, Kwong Fai Wong, Kwong Fai Wong, Alan Prem Kumar, Alan Prem Kumar, Alan Prem Kumar, John M. Luk, John M. Luk, John M. Luk, Kam M. Hui, Kam M. Hui, Gautam Sethi, Gautam Sethi, Tapas K. Kundu
Journal: Cancer Research (2013)

Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third cause of global cancer mortality. Activation of signal transducer and activator of transcription 3 (STAT3) is commonly encountered in tumor cells and is a critical mediator of oncogenic signaling in HCC and controls the expression of several genes involved in proliferation, survival, metastasis and angiogenesis. Current drug-targeted therapies, besides being expensive, are associated with serious side effects and morbidity. Thus, novel agents that can suppress STAT3 activation have potential for both prevention and treatment of HCC. In the present report, we investigated whether the potent HAT/KAT inhibitor, garcinol, (a polyisoprenylated benzophenone), could suppress STAT3 activation in HCC cells and nude mice model. We found that garcinol could inhibit constitutive STAT3 activation in a dose- and time-dependent manner both by inhibiting STAT3 phosphorylation and acetylation in HCC cells. When investigated for molecular mechanism(s), we found that garcinol interferes with the dimer formation of STAT3 thereby inhibits its nuclear localization. Computational modeling showed that garcinol could bind to the SH2 domain of STAT3 and suppresses its dimerization in vitro. To understand the cellular mechanism(s) of inhibition of STAT3 function by garcinol, we observed that upon inhibition of STAT3 dimerization by garcinol, STAT3 DNA binding ability gets repressed. The inhibition of STAT3 activation by garcinol led to the suppression of various gene products involved in proliferation, survival, and angiogenesis. Finally, when administered i.p., garcinol inhibited the growth of human HCC xenograft tumors in male athymic nu/nu mice. In conclusion, results from in vitro and in vivo studies suggest that garcinol exerts its anti-proliferative and pro-apoptotic effects through suppression of STAT3 signaling cascade in HCC by inhibiting its phosphorylation, acetylation and ultimately dimerization. Citation Format: Muthu K. Shanmugam, Snehajyoti Chatterjee, Rajendran Peramaiyan, Feng Li, Parijat Senapati, Kwong Fai Wong, Kwong Fai Wong, Alan Prem Kumar, Alan Prem Kumar, Alan Prem Kumar, John M. Luk, John M. Luk, John M. Luk, Kam M. Hui, Kam M. Hui, Gautam Sethi, Gautam Sethi, Tapas K. Kundu. Targeted inhibition of STAT3 dimerization by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4711. doi:10.1158/1538-7445.AM2013-4711
P1174 THE NOVEL ss469415590 POLYMORPHISM PREDICTS RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS TYPE 1 INFECTION
Authors: L. Covolo, S. Bibert, F. Donato, P.-Y. Bochud, M. Lagging, F. Negro, G. Fattovich
Journal: Journal of Hepatology (2014)
PWE-108 Assessment of the Mucosal Microbiota in Inflammatory Bowel Disease
Authors: N A Kennedy, D Hildebrand, S H Berry, J Satsangi, G L Hold
Journal: Gut (2013)

<h3>Introduction</h3> Great progress has been made in understanding the pathophysiology of Crohn’s disease (CD) and ulcerative colitis (UC), and it is now widely believed that dysregulation of the relationship between the gut microbiota and the host immune system is central to both diseases. Most published studies to date have focused on assessing the microbiota found in faecal samples, but it is increasingly recognised that this may not be an accurate reflection of what is happening at the mucosal level. The Aims of this study were to establish a bioresource of IBD patients and controls, and to use this to assess differences in gut microbiota between cases and controls and between different IBD subphenotypes. <h3>Methods</h3> Patients undergoing colonoscopy and flexible sigmoidoscopy were recruited to the South East Scotland IBD bioresource. Mucosal biopsies were obtained and snap-frozen using dry ice. DNA was then extracted using a QIAGEN spin column-based method. Blood and serum samples were also biobanked for genetic, epigenetic and metabolomics analysis. Quantitative PCR was used to measure the relative abundance of different bacterial classes compared to the total measured with universal primers. Statistical analysis was done using Mann Whitney U, chi squared and Fisher’s exact tests using R 2.15.2. <h3>Results</h3> After quality control, results were available from 147 biopsies taken from 84 patients. There were 20 patients with CD, 26 with UC, 2 IBD-U, 20 healthy controls (HC) and 16 with other diagnoses. Median age was 45 years (interquartile range [IQR] 28–50) in the CD group, 51 y (38–63) in the UC group and 39 (30–49) in the HC group. There were no significant differences in age or sex distribution between the CD, UC and HC groups. There was a statistically significant reduction in CD compared with HC in Ruminococcaceae (p = 0.002, figure 1), Lachnospiraceae (p = 0.046) and Bacteroides (0.024) and an increase in Enterobacteriaceae (p = 0.046). Comparing UC with HC, there was a significant increase in Enterobacteriaceae (p = 0.025), but no difference in the other classes. There were no significant differences in any bacterial class between biopsies taken from inflamed and non-inflamed sites in IBD patients. <h3>Conclusion</h3> This study confirms reductions in Ruminococcaceae described previously in CD, and increased Enterobacteriaceae in both CD and UC. The presence of paired DNA and serum samples offers the exciting potential to explore the relationship between the gut microbiota, epigenetic and metabolomics changes. <h3>Disclosure of Interest</h3> None Declared.
BM-13 * THE (F)UTILITY OF PREDICTIVE MODELS
Authors: A. Hanna, D. Hunter Boggs, P. Sperduto, Y. Kwok, S. Feigenberg, M. Simard, M. Mehta
Journal: Neuro-Oncology (2014)

PURPOSE/OBJECTIVES: Physician estimates of cancer patients' survival are notoriously inaccurate. A number of models have been developed in an effort to better predict patient lifespan based on clinical factors. The Graded Prognostic Assessment (GPA), most recently published in 2012 by Sperduto et al, estimates median survival (MS) for patients who had undergone treatment for new brain metastases from June 1993 to January 2010. While independently validated in numerous studies, we investigated the applicability of the GPA model in the modern era for a smaller cohort of patients with brain metastases who were specifically selected for SRS by retrospectively calculating the diagnosis-specific GPA predicted median survival for patients with brain metastases treated with SRS at our institution between 2006 and 2012. RESULTS: 100 patients underwent SRS; 73 received whole brain radiation therapy. Observed (O) and predicted (P) MS were 13.3 and 9.4 months. The difference between predicted and actual survival was computed for each patient, and the mean difference was 10.8 months (95% CI, 8.95 - 14.8 months); the mean actual/predicted ratio was 2.07 (95% CI, 1.64 - 2.50). Compared to the predicted, actual survival was 25/35/50% longer (an arbitrarily chosen yet clinically significant amount of time) in almost half (53/49/48%) of our patients. Even when KPS was overestimated (increasing GPA predicted survival), actual survival 25/35/50% longer than predicted survival was observed in 49/46/44% of patients. CONCLUSIONS: Our deliberate selection bias of recently treated patients with modern imaging and more advanced therapies confirms that clinical models such as the GPA must be used with awareness of the current clinical setting as well as a full understanding of the model and its derivation to be of greatest benefit.
Dilatation of Renal Artery Distal to Stenosis Demonstrated Using Acetazolamide Tc-99m MAG3 Scintigraphy
Authors: Y Horita, K Hayashida, S Takishita, S Kohno, Y Kawano
Journal: Clinical Nuclear Medicine (2001)

HORITA, YOSHIO M.D.*§; HAYASHIDA, KOHEI M.D.,†; TAKISHITA, SHUICHI M.D.,‡; KOHNO, SHIGERU M.D.§; KAWANO, YUHEI M.D.* Author Information
Neuro-Oncology turns a page
Authors: W. K. A. Yung
Journal: Neuro-Oncology (2010)

Happy 2010 to all our readers, and welcome to a new Neuro-Oncology. After months of previews and updates, you now hold in your hands the first issue of the journal published by Oxford Journals and the first published on a monthly schedule.

First, a little about our new partner. Oxford Journals is a division of Oxford University Press, which is a department of Oxford University and which has been publishing since 1478—more than half a millennium. The Journals division, which was established just over a century ago, publishes more than 200 academic and research journals covering a broad range of subject areas, two-thirds of which are, like Neuro-Oncology, published in collaboration with learned societies or other international organizations.

One of the things we particularly like about our new partner is that its stated mission—to bring the highest quality research to the widest possible audience—is very much in keeping with the journal's and the Society for Neuro-Oncology's. We are looking forward to capitalizing on Oxford's truly global reach, which means more than simply selling publications on a worldwide basis—the Press has offices not only at its home base in the United Kingdom but also throughout Asia, Africa, Europe, Australia, and North and South America.

Our new partner promises to provide Neuro-Oncology's authors with an excellent level of service, including a move away from traditional transfer of copyright to the granting of licenses that allow the research to be as widely disseminated as possible. Oxford Journals is also one of the first publishers to experiment with open access in publishing through its Oxford Open initiative. This option allows authors to, for a modest fee, make their articles immediately available to the scientific community at no charge, which helps ensure that important results are read (and cited) as soon as possible.

The Press' developing countries initiatives, whereby institutions in traditionally underserved nations are granted access to publications at either deeply discounted prices or even free, are another vital aspect of our new affiliation and are very much in keeping with the Society's international outreach goals.

We are also happy to report that authors and reviewers will not have to learn a new system for online submission and reviewing of manuscripts, or even be bothered with obtaining new passwords and so on; Editorial Manager, the web-based submission and tracking system we've used for the last several years, is fully supported by Oxford. The journal website, on the other hand, does have a new home: http://neuro-oncology.oxfordjournals.org. While you are there, don't forget to sign up for electronic Table of Contents and Advance Access alerts, so that you can access each new issue of the journal online as soon as it is posted. If you have been receiving alerts from Duke University Press, you will need to register again due to data protection regulations.
Abstract 5245: Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients
Authors: Galatea Kallergi, Georgios Konstantinidis, Maria Papadaki, Sophia Agelaki, Dimitris Mavroudis, Christos Stournaras, Vassilis Georgoulias
Journal: Cancer Research (2011)

Abstract Introduction: Metastasis has been associated with the presence of circulating (CTCs) and disseminated (DTCs) tumor cells in peripheral blood and bone marrow of breast cancer patients, respectively. Recent studies have confirmed that the detection of CTCs and DTCs represents a strong and independent prognostic factor for decreased disease-free and overall survival. However, it is not clear so far whether all CTCs are capable to generate metastasis or some of them are destined to die. The aim of the present study was to analyze the presence of apoptotic CTCs in patients with early and metastatic breast cancer. Methods: Double staining immunofluorescent (IF) expreriments were performed in peripheral blood mononuclear cells (PBMC) cytospins of patients with early (n=23) and metastatic breast cancer (n=29), prior to the initiation of adjuvant and first-line chemotherapy, respectively. Pancytokeratin A45-B/B3 antibody (as a marker of CK-positive cells) was coupled with either M30 (marker of apoptotic cells) or Ki67 (marker of proliferating cells) antibodies. Apoptotic CTCs were also evaluated using a polycaspase detection kit. Results: Significantly lower proportions of apoptotic CTCs were detected in metastatic compared to early breast cancer patients using the polycaspase kit (10.6% vs 32.8%, p=0.008). These results were confirmed with M30 staining (36.0% vs 59.3%, in early and metastatic disease, respectively, p=0.048). The median percentage of apoptotic CTCs per patient was also lower in advanced compared to early disease patients (0% vs 40% with the polycaspase kit and 15% vs 69% with M30 staining). Ki67 positive CTCs were identified in 56% of metastatic patients, while 36% of their CTCs were double positive (CK+Ki67+). Conclusions: Apoptotic CTCs are more common in early compared to metastatic breast cancer, probably related to the disease progression. The presence of apoptotic CTCs in breast cancer patients may provide useful prognostic information and could be used to monitor the effectiveness of therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5245. doi:10.1158/1538-7445.AM2011-5245
Preferential Transmission of Diabetic Alleles within the HLA Gene Complex
Authors: Constance M. Vadheim, Jerome I. Rotter, Noel K. Maclaren, William J. Riley, C. Elizabeth Anderson
Journal: New England Journal of Medicine (1986)

Several studies suggest a higher incidence of insulin-dependent diabetes mellitus (IDDM) among the offspring of men with the disease than among those of female diabetics. Differential transmission by the father of genes that predispose to diabetes may explain this phenomenon. To test this hypothesis, we examined parent-to-offspring transmission of HLA haplotypes and DR (D-related) alleles in 107 nuclear families in which a child had IDDM. We observed that fathers with a DR4 allele were significantly more likely to transmit this allele to their diabetic or nondiabetic children than were mothers with a DR4 allele (72.1 vs. 55.6 percent, P<0.001). No differences between parents were observed for HLA-DR3; however, DR3 was transmitted significantly more than 50 percent of the time from either parent (P<0.001). These data suggest that differential parental transmission of the HLA-DR4-linked diabetes-predisposing allele may explain the higher risk of diabetes among children of diabetic fathers than among those of diabetic mothers. In addition, the excess transmission of diabetogenic HLA alleles from parent to offspring may explain how these deleterious genes continue to recur at such high frequencies in the general population. (N Engl J Med 1986; 315:1314–8.)
OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome”
Authors: Y. Yazici, Y. Bata, C. J. Swearingen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> We had developed a PRO measure for Behcet Syndrome (BS) BSAS (Behcet Syndrome Activity Scale), for use as an outcome measure in order to determine need for treatment changes, leading to more aggressive treatment and possible "treating to target" criteria <h3>Objectives</h3> To determine if change in treatment is associated with changes in the BSAS, physician global, (MDGL) and RAPID3 scores. <h3>Methods</h3> All BS patients seen at the center completed an MDHAQ, and a BSAS. Treatment changes defined as first line (colchicine, hydroxychloroquine, low dose prednisone), second line (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil) and third line (biologic agents-TNF inhibitor) were identified and then the predictive value of change in therapy with BSAS, RAPID3 and MDGL were estimated using general linear mixed models. <h3>Results</h3> 544 patients (female 74%, mean disease duration 4.9 years, age 35) over 1474 observations (average 3.5 observations per patient) were analyzed. BSAS quantified more differences than MDGL and RAPID3, identifying significant changes between no therapy and first line, third line, combination of first and second and all three (Table). All three outcomes were able to distinguish between no therapy and use of combination of first and second line therapies as well as usage of all three. <h3>Image/graph</h3> <h3>Conclusions</h3> BSAS was the measure most strongly and commonly associated with therapy changes. Both MDGL and RAPID3 were more predictive of later level treatment changes where as BSAS was also useful early on with lower levels of disease activity. A patient outcome measure such as BSAS may be useful in documenting treatment responses in Behcet syndrome patients in routine care and may be developed further as a "treat to target" tool for BS. <h3>Disclosure of Interest</h3> None Declared